Why the study?
Does radiofrequency catheter ablation using EnSite non-contact mapping improve heart rate and clinical symptoms in patients with drug-refractory inappropriate sinus tachycardia?
Does radiofrequency catheter ablation using EnSite non-contact mapping improve heart rate and clinical symptoms in patients with drug-refractory inappropriate sinus tachycardia?
Radiofrequency catheter ablation using non-contact mapping to target breakout sites in the tall P-wave zone is a safe and effective strategy for treating drug-refractory inappropriate sinus tachycardia.
May support RFCA for heart rate control in refractory IST; leaves open need for randomized trials before broader adoption.
OBJECTIVES: The present study evaluated the clinical benefits of a new therapeutic method of radiofrequency catheter ablation (RFCA) using an EnSite system for inappropriate sinus tachycardia (IST). MATERIALS AND METHODS: Six patients with debilitating IST underwent RFCA using EnSite. Using the beta-adrenergic blocker and agonist, the heart rate was controlled between 70 to 150 bpm before and after the RFCA. The areas of the breakout sites (BOSs) were clearly distinguished between those from the normal P-wave zones during rates of less than 100 bpm and those from more upper rate sites during rates of more than 100 bpm using the EnSite system, in accordance with the appearance of tall P-waves (tall P-wave zone) in the IST patients. This was selected as the target for ablation. RESULTS: After the RFCA, the BOSs observed during heart rates of more than 100 bpm moved completely from the tall P-wave zone to the normal P-wave zone in the IST patients. The total number of heart beats and average heart beat on the 24-h Holter monitoring decreased statistically from that before the RFCA to that after, and no adverse heart rate responses was observed after the RFCA. Before the RFCA, the brain natriuretic peptide was elevated, New York Heart Association functional class was worse, and there was an impaired exercise tolerance observed with exercise electrocardiogram testing. The RFCA for the IST significantly improved those parameters. CONCLUSION: This new therapeutic method for IST using EnSite is effective and produces clinical benefits.
No takes yet. Share an insight, caveat, or question.
Takemoto et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: